Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Edema | 5 | 2022 | 27 | 2.080 |
Why?
|
| Diabetic Retinopathy | 5 | 2022 | 84 | 1.930 |
Why?
|
| Thermotolerance | 2 | 2024 | 5 | 1.740 |
Why?
|
| Visual Acuity | 7 | 2022 | 537 | 1.520 |
Why?
|
| Ranibizumab | 3 | 2019 | 12 | 1.160 |
Why?
|
| Climate Change | 3 | 2024 | 63 | 1.120 |
Why?
|
| Chiroptera | 2 | 2025 | 17 | 1.110 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2021 | 110 | 1.090 |
Why?
|
| Starvation | 2 | 2024 | 17 | 0.990 |
Why?
|
| Disease Reservoirs | 2 | 2025 | 36 | 0.940 |
Why?
|
| One Health | 1 | 2024 | 3 | 0.890 |
Why?
|
| Ophthalmic Solutions | 1 | 2024 | 88 | 0.820 |
Why?
|
| Anesthetics, Local | 1 | 2024 | 85 | 0.790 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2019 | 341 | 0.680 |
Why?
|
| Anatomy | 1 | 2020 | 13 | 0.670 |
Why?
|
| Macular Degeneration | 1 | 2021 | 91 | 0.660 |
Why?
|
| Bees | 4 | 2026 | 52 | 0.660 |
Why?
|
| Deep Brain Stimulation | 9 | 2021 | 453 | 0.650 |
Why?
|
| Status Epilepticus | 3 | 2020 | 157 | 0.640 |
Why?
|
| Phenytoin | 2 | 2020 | 57 | 0.630 |
Why?
|
| Valproic Acid | 2 | 2020 | 161 | 0.590 |
Why?
|
| Anticonvulsants | 3 | 2020 | 391 | 0.590 |
Why?
|
| Laser Coagulation | 1 | 2019 | 109 | 0.570 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 173 | 0.560 |
Why?
|
| Intravitreal Injections | 5 | 2022 | 40 | 0.530 |
Why?
|
| Dystonic Disorders | 4 | 2022 | 98 | 0.510 |
Why?
|
| Students, Medical | 1 | 2020 | 350 | 0.480 |
Why?
|
| Dystonia | 4 | 2022 | 174 | 0.450 |
Why?
|
| Hot Temperature | 2 | 2024 | 144 | 0.410 |
Why?
|
| Movement Disorders | 3 | 2026 | 224 | 0.410 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 886 | 0.410 |
Why?
|
| Globus Pallidus | 4 | 2021 | 68 | 0.400 |
Why?
|
| Double-Blind Method | 7 | 2020 | 1634 | 0.310 |
Why?
|
| Tomography, Optical Coherence | 5 | 2019 | 463 | 0.270 |
Why?
|
| Informed Consent | 2 | 2024 | 343 | 0.260 |
Why?
|
| Humans | 36 | 2026 | 131504 | 0.260 |
Why?
|
| Pollination | 1 | 2026 | 2 | 0.250 |
Why?
|
| Apathy | 1 | 2026 | 13 | 0.240 |
Why?
|
| Plants | 1 | 2026 | 48 | 0.240 |
Why?
|
| Child, Preschool | 13 | 2024 | 15047 | 0.230 |
Why?
|
| Disease Resistance | 1 | 2025 | 22 | 0.230 |
Why?
|
| Ecology | 1 | 2024 | 17 | 0.220 |
Why?
|
| Desiccation | 1 | 2024 | 46 | 0.220 |
Why?
|
| Virology | 1 | 2024 | 31 | 0.220 |
Why?
|
| Adolescent | 16 | 2024 | 20917 | 0.220 |
Why?
|
| Male | 25 | 2026 | 65158 | 0.220 |
Why?
|
| Animals | 6 | 2026 | 34341 | 0.220 |
Why?
|
| Propoxycaine | 1 | 2024 | 3 | 0.220 |
Why?
|
| Acclimatization | 1 | 2024 | 21 | 0.210 |
Why?
|
| Female | 26 | 2026 | 71087 | 0.210 |
Why?
|
| Immune Tolerance | 1 | 2025 | 159 | 0.210 |
Why?
|
| Body Temperature Regulation | 1 | 2024 | 51 | 0.210 |
Why?
|
| Adaptive Immunity | 1 | 2024 | 100 | 0.210 |
Why?
|
| Single-Blind Method | 1 | 2024 | 241 | 0.200 |
Why?
|
| Congresses as Topic | 1 | 2024 | 186 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2021 | 12936 | 0.200 |
Why?
|
| Adaptation, Physiological | 1 | 2025 | 261 | 0.200 |
Why?
|
| Child | 16 | 2024 | 26239 | 0.190 |
Why?
|
| Cold-Shock Response | 1 | 2022 | 5 | 0.190 |
Why?
|
| Macula Lutea | 2 | 2019 | 25 | 0.190 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 2 | 0.180 |
Why?
|
| Bevacizumab | 2 | 2019 | 59 | 0.180 |
Why?
|
| Genome | 1 | 2025 | 472 | 0.180 |
Why?
|
| Myoclonus | 1 | 2022 | 32 | 0.180 |
Why?
|
| Drug Implants | 1 | 2022 | 41 | 0.180 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2021 | 2 | 0.180 |
Why?
|
| Virus Diseases | 1 | 2024 | 285 | 0.180 |
Why?
|
| Temperature | 1 | 2022 | 294 | 0.180 |
Why?
|
| Lymphedema | 1 | 2021 | 19 | 0.180 |
Why?
|
| Middle Aged | 12 | 2026 | 28839 | 0.180 |
Why?
|
| Lesch-Nyhan Syndrome | 1 | 2021 | 11 | 0.170 |
Why?
|
| Sports | 1 | 2022 | 64 | 0.170 |
Why?
|
| Emergency Medical Services | 2 | 2024 | 421 | 0.170 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 2020 | 3 | 0.170 |
Why?
|
| Young Adult | 12 | 2021 | 10092 | 0.170 |
Why?
|
| Steroids | 1 | 2022 | 172 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 289 | 0.160 |
Why?
|
| Cadaver | 1 | 2020 | 120 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2020 | 15 | 0.160 |
Why?
|
| Population Groups | 1 | 2020 | 31 | 0.160 |
Why?
|
| Adolescent Behavior | 1 | 2022 | 171 | 0.160 |
Why?
|
| Gonorrhea | 1 | 2020 | 42 | 0.160 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 166 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2022 | 350 | 0.150 |
Why?
|
| Retinal Perforations | 1 | 2019 | 5 | 0.150 |
Why?
|
| Vitreous Detachment | 1 | 2019 | 6 | 0.150 |
Why?
|
| Fibrinolysin | 1 | 2019 | 10 | 0.150 |
Why?
|
| Visual Field Tests | 1 | 2019 | 50 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 5120 | 0.150 |
Why?
|
| Seizures | 1 | 2024 | 889 | 0.140 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2018 | 22 | 0.140 |
Why?
|
| Adult | 15 | 2026 | 31666 | 0.140 |
Why?
|
| Hyperkinesis | 1 | 2018 | 27 | 0.140 |
Why?
|
| Educational Measurement | 1 | 2020 | 317 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2026 | 901 | 0.140 |
Why?
|
| Visual Fields | 1 | 2019 | 141 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 169 | 0.130 |
Why?
|
| Phenotype | 3 | 2022 | 4517 | 0.130 |
Why?
|
| Electric Power Supplies | 1 | 2017 | 17 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 391 | 0.130 |
Why?
|
| Infant | 5 | 2024 | 13300 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2024 | 725 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 155 | 0.120 |
Why?
|
| Cerebellar Ataxia | 1 | 2016 | 72 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1008 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 782 | 0.110 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2014 | 2 | 0.110 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Melanosis | 1 | 2014 | 9 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2019 | 781 | 0.110 |
Why?
|
| Nevus, Pigmented | 1 | 2014 | 30 | 0.110 |
Why?
|
| Efferent Pathways | 1 | 2014 | 7 | 0.110 |
Why?
|
| Diazepam | 1 | 2014 | 20 | 0.110 |
Why?
|
| Lorazepam | 1 | 2014 | 12 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 300 | 0.100 |
Why?
|
| Disclosure | 1 | 2014 | 149 | 0.100 |
Why?
|
| Time Factors | 3 | 2019 | 6273 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1624 | 0.090 |
Why?
|
| Exome | 1 | 2016 | 1076 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1023 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 934 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2022 | 6485 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5277 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 468 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1745 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2306 | 0.080 |
Why?
|
| Neuronavigation | 1 | 2009 | 10 | 0.080 |
Why?
|
| Aged | 7 | 2026 | 21238 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 1254 | 0.080 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 187 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 3911 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 130 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2009 | 81 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2019 | 110 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2019 | 251 | 0.070 |
Why?
|
| Age Distribution | 1 | 2020 | 429 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2019 | 54 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2646 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 547 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 6177 | 0.070 |
Why?
|
| Hypotension | 1 | 2019 | 184 | 0.070 |
Why?
|
| Adenylyl Cyclases | 1 | 2026 | 61 | 0.060 |
Why?
|
| Biodiversity | 1 | 2026 | 77 | 0.060 |
Why?
|
| Ecosystem | 1 | 2026 | 100 | 0.060 |
Why?
|
| Ubiquitins | 1 | 2025 | 38 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1230 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 2025 | 157 | 0.050 |
Why?
|
| Voice Training | 1 | 2024 | 6 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6916 | 0.050 |
Why?
|
| Species Specificity | 1 | 2025 | 519 | 0.050 |
Why?
|
| Midazolam | 1 | 2024 | 46 | 0.050 |
Why?
|
| Speech Therapy | 1 | 2024 | 15 | 0.050 |
Why?
|
| Valsartan | 1 | 2023 | 26 | 0.050 |
Why?
|
| Dysarthria | 1 | 2024 | 26 | 0.050 |
Why?
|
| Spain | 1 | 2023 | 62 | 0.050 |
Why?
|
| Public Opinion | 1 | 2024 | 63 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2023 | 72 | 0.050 |
Why?
|
| Age Factors | 1 | 2020 | 2870 | 0.050 |
Why?
|
| Electrodes, Implanted | 2 | 2017 | 174 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2023 | 277 | 0.050 |
Why?
|
| Sarcoglycans | 1 | 2022 | 8 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 139 | 0.050 |
Why?
|
| Phylogeny | 1 | 2025 | 707 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2026 | 844 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2021 | 86 | 0.040 |
Why?
|
| Pantothenic Acid | 1 | 2020 | 6 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 529 | 0.040 |
Why?
|
| Laryngeal Diseases | 1 | 2020 | 30 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 137 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 149 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 131 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 43 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 92 | 0.040 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 47 | 0.040 |
Why?
|
| Plasma Kallikrein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 69 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 513 | 0.040 |
Why?
|
| Vitreous Body | 1 | 2019 | 56 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2019 | 29 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 372 | 0.040 |
Why?
|
| Cytokines | 1 | 2025 | 1347 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2021 | 494 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 259 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 409 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 331 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 650 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 685 | 0.030 |
Why?
|
| Peroxisomal Multifunctional Protein-2 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Depression | 1 | 2026 | 1338 | 0.030 |
Why?
|
| Genomics | 1 | 2025 | 1624 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 100 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2020 | 929 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 692 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 865 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 631 | 0.030 |
Why?
|
| Third-Party Consent | 1 | 2014 | 27 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2205 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11794 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 421 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 62 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 195 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4037 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 228 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1217 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 588 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3834 | 0.020 |
Why?
|
| Prevalence | 1 | 2020 | 2692 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17648 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 397 | 0.020 |
Why?
|
| Differential Threshold | 1 | 2011 | 9 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1024 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 157 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 141 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 566 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2107 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2011 | 111 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2011 | 79 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 173 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 432 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 722 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1478 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 120 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2009 | 98 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 289 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2655 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 155 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 244 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 556 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 1956 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2009 | 285 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 955 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1516 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 397 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3411 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 3452 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2297 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8589 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 3090 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 3237 | 0.010 |
Why?
|